Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
belinostat
HDAC inhibitor · Antineoplastic agent
HDAC inhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
D
FDA category + note
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- BaricitinibSevereDatabaseDDInter
- CertolizumabSevereDatabaseDDInter
- CladribineSevereDatabaseDDInter
Mechanism
Belinostat is an HDAC inhibitor. Inhibition of HDAC activity causes the accumulation of acetyl groups on histone lysine residues, an open chromatin structure, and activation of target genes that are selectively repressed in tumors.
Indications
peripheral T-cell lymphoma
Side effects
Serious
- hematological toxicity
- infections
- hepatotoxicity
Pregnancy & lactation
Pregnancy
D
Drug interactions
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Clozapine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Deferiprone
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Etanercept
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Fingolimod
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Golimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Infliximab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Leflunomide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Lomitapide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Related guidelines
Other HDAC inhibitor drugs
Ask House about belinostat
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team